Eli Lilly Makes License Deal Payment, Equity Investment in South Korean Biotech ABL Bio

05:53 AM EST, 12/26/2025 (MT Newswires) -- Eli Lilly (LLY.SW) will make an upfront payment of $40 million and $15 million in equity investment to ABL Bio as part of a deal related to the South Korean biotechnology company's bispecific antibody platform. The license, research and collaboration agreement is for Grabody platform, through which ABL Bio and the Switzerland-listed pharmaceutical group are carrying out joint research and development on multiple therapeutic candidates, according to a Thursday release. The agreements were previously announced in November. ABL intends to use the funds to further advance research and development on its core technologies.